Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain - Specific glycoprotein H epitopes

被引:36
作者
Ishibashi, Kei
Tokumoto, Tadahiko
Tanabe, Kazunari
Shirakawa, Hiroki
Hashimoto, Koichi
Kushida, Nobuhiro
Yanagida, Tomohiko
Inoue, Naoki
Yamaguchi, Osamu
Toma, Hiroshi
Suzutani, Tatsuo
机构
[1] Fukushima Med Univ, Dept Microbiol, Fukushima 9601295, Japan
[2] Fukushima Med Univ, Dept Urol, Fukushima, Japan
[3] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan
[4] Natl Inst Infect Dis, Dept Virol 1, Tokyo, Japan
基金
日本学术振兴会;
关键词
ALLOGRAFT-REJECTION; INFECTION; RECIPIENTS; DISEASE; PROPHYLAXIS; RISK; ANTIGEN; VALACYCLOVIR; GANCICLOVIR; THERAPY;
D O I
10.1086/518571
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Cytomegalovirus ( CMV) is the most important pathogen affecting the outcome of renal transplantation. The combination of CMV-seronegative transplant recipients with CMV-seropositive transplant donors places recipients at the highest risk of CMV disease. In cases of congenital CMV infection, existing immunity only partially protected mothers from reinfection with a different genotypic strain. The effect of differences in infected CMV strains between CMV-seropositive transplant donors and CMV seropositive transplant recipients on the outcome of transplantation remains unclear. Methods. In this prospective multicenter study, the presence of antibodies against strain-specific glycoprotein H epitopes in 84 CMV-seropositive transplant donor/CMV-seropositive transplant recipient renal transplantation cases were determined, and their relationships to acute transplant rejection, CMV infection, degree of antigenemia, and CMV disease were evaluated. Results. Among the 84 donor/recipient pairs, 45 and 32 had matched and mismatched strain-specific glycoprotein H antibodies, respectively. Acute transplant rejection in the mismatched group was more frequent than it was in the matched group ( 63% vs. 22%; P = .005). CMV disease was also more frequently observed in the mismatched group ( 28% vs. 9%; P = .026). The mismatched group had a higher level of antigenemia (P = 0.19). Conclusions. Our results illustrate more adverse events in the cases with a CMV-seropositive transplant donor and a CMV-seropositive transplant recipient in which the glycoprotein H antibodies are mismatched, suggesting that reinfection with a different CMV strain results in more complications.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 33 条
[21]   Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection [J].
Reischig, T ;
Jindra, P ;
Mares, J ;
Cechura, M ;
Svecová, M ;
Hes, O ;
Opatrny, K ;
Treska, V .
TRANSPLANTATION, 2005, 79 (03) :317-324
[22]   An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA [J].
Rothe, M ;
Pepperl-Klindworth, S ;
Lang, D ;
Vornhagen, R ;
Hinderer, W ;
Weise, K ;
Sonneborn, HH ;
Plachter, B .
JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (04) :719-729
[23]   Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation [J].
Ruttmann, Elfriede ;
Geltner, Christian ;
Bucher, Brigitte ;
Ulmer, Hanno ;
Hoefer, Daniel ;
Hangler, Herbert B. ;
Semsroth, Severin ;
Margreiter, Raimund ;
Laufer, Guenther ;
Mueller, Ludwig C. .
TRANSPLANTATION, 2006, 81 (10) :1415-1420
[24]   Pre-emptive therapy of CMVpp65 recipients with oral ganciclovir:: a antigen positive renal transplant randomized, comparative study [J].
Sagedal, S ;
Nordal, KP ;
Hartmann, A ;
Midtvedt, K ;
Foss, A ;
Asberg, A ;
Degré, M ;
Fauchald, P ;
Rollag, H .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (09) :1899-1908
[25]   A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients [J].
Sagedal, S ;
Nordal, KP ;
Hartmann, A ;
Degré, M ;
Holter, E ;
Foss, A ;
Osnes, K ;
Leivestad, T ;
Fauchald, P ;
Rollag, H .
TRANSPLANTATION, 2000, 70 (08) :1166-1174
[26]   Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response [J].
Shimamura, M ;
Mach, M ;
Britt, WJ .
JOURNAL OF VIROLOGY, 2006, 80 (09) :4591-4600
[27]   HIGH-DOSE ACYCLOVIR COMPARED WITH SHORT-COURSE PREEMPTIVE GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN LIVER-TRANSPLANT RECIPIENTS - A RANDOMIZED TRIAL [J].
SINGH, N ;
YU, VL ;
MIELES, L ;
WAGENER, MM ;
MINER, RC ;
GAYOWSKI, T .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (05) :375-381
[28]   Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation [J].
Slifkin, M ;
Ruthazer, R ;
Freeman, R ;
Bloom, J ;
Fitzmaurice, S ;
Fairchild, R ;
Angelis, M ;
Cooper, J ;
Barefoot, L ;
Rohrer, R ;
Snydman, DR .
LIVER TRANSPLANTATION, 2005, 11 (12) :1597-1602
[29]   Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation [J].
Tanabe, K ;
Tokumoto, T ;
Ishikawa, N ;
Koyama, I ;
Takahashi, K ;
Fuchinoue, S ;
Kawai, T ;
Koga, S ;
Yagisawa, T ;
Toma, H ;
Ota, K ;
Nakajima, H .
TRANSPLANTATION, 1997, 64 (12) :1721-1725
[30]  
Toupance O, 2000, TRANSPLANT INT, V13, P413, DOI 10.1007/s001470050723